'New drug' presentation slideshows

New drug - PowerPoint PPT Presentation


Using Genomics in Clinical Trial Design

Using Genomics in Clinical Trial Design

Using Genomics in Clinical Trial Design. Richard Simon, D.Sc. Chief, Biometric Research Branch National Cancer Institute http://linus.nci.nih.gov. BRB Website http://linus.nci.nih.gov/brb. Powerpoint presentations and audio files Reprints & Technical Reports BRB-ArrayTools software

By LeeJohn
(361 views)

Myers PSYCHOLOGY

Myers PSYCHOLOGY

Myers PSYCHOLOGY . Module 4 Neural and Hormonal Systems. Neural Communication. Biological Psychology branch of psychology concerned with the links between biology and behavior

By KeelyKia
(347 views)

Drug design and testing,

Drug design and testing,

Drug design and testing,. Drug Names. Chemical name- describes its molecular structure and distinguishes it from other drugs. Generic name- is determined by the pharmaceutical company along with the a special organization known as the U.S. Adopted names Council.

By arlo
(206 views)

STANDARD COURSE IN CLINICAL TRIAL

STANDARD COURSE IN CLINICAL TRIAL

STANDARD COURSE IN CLINICAL TRIAL. PIENGTHONG NARAKORN May 23, 2008. OUTLINE: March 24, 2008. From R&D product to licensing Study design & research methodology for clinical trials Proposal development Grant hunting, fund management, research administration & human resource management

By brianna
(300 views)

Joseph A. DiMasi, Ph.D. Tufts Center for the Study of Drug Development Tufts University The New England Drug Metabolism

Joseph A. DiMasi, Ph.D. Tufts Center for the Study of Drug Development Tufts University The New England Drug Metabolism

The Economics of New Drug Development: Costs, Risks, and Returns. Joseph A. DiMasi, Ph.D. Tufts Center for the Study of Drug Development Tufts University The New England Drug Metabolism Group Spring Meeting Cambridge, MA, March 12, 2008. Agenda. Drug development times

By taite
(299 views)

Fraud & Misconduct at Investigator Sites – A CRA’s Perspective

Fraud & Misconduct at Investigator Sites – A CRA’s Perspective

Fraud & Misconduct at Investigator Sites – A CRA’s Perspective. Paul Below Clinical Research Consultant P. Below Consulting, Inc. Advanced Monitoring & Site Management Workshop Atlanta Chapter - ACRP October 15, 2005. Disclosure. I have a consulting relationship with the following:

By dixon
(131 views)

Databases or Registries? Points to Consider

Databases or Registries? Points to Consider

Databases or Registries? Points to Consider. Mary Lou Skovron, DrPH Group Director, Global Epidemiology Bristol-Myers Squibb FDA/Industry Statistics Workshop September 29, 2006. Overview. Claims databases Types Advantages Limitations Registries Types Advantages Limitations Examples

By abe
(192 views)

Correlation and the logic of significance testing

Correlation and the logic of significance testing

Correlation and the logic of significance testing. Practice.

By malcolm
(513 views)

Premarket Testing and Validation

Premarket Testing and Validation

Premarket Testing and Validation. "The greatest lesson in life is to know that even fools are right sometimes" Sir Winston Churchill . Standard Tests. Cycle testing [on/off, etc.] Typical use testing [Elec. & Mech. Test, typical, aim for MTBF values]

By sofia
(154 views)

Complying with FDA/OIG Rules

Complying with FDA/OIG Rules

Complying with FDA/OIG Rules. Wayne L. Pines August 24, 2006. Wayne Pines. Consultant to pharma/devices industries on advertising/ promotion issues, crisis control Former Associate Commissioner for Public Affairs, FDA Author/editor, FDA Advertising and Promotion Manual, 10 others books .

By dolores
(167 views)

Detecting Differentially Expressed Genes

Detecting Differentially Expressed Genes

Detecting Differentially Expressed Genes. Pengyu Hong 09/13/2005. Background (Microarray). Extract RNA. Cells. Background. Extract RNA. Cells. Background. Extract RNA. Cells. Background. Extract RNA. Cells. Background. Extract RNA. Cells. 10 4 + genes. Background. Extract RNA.

By abrial
(128 views)

Design & Analysis of Phase III Trials for Predictive Oncology

Design & Analysis of Phase III Trials for Predictive Oncology

Design & Analysis of Phase III Trials for Predictive Oncology. Richard Simon Chief, Biometric Research Branch National Cancer Institute http://brb.nci.nih.gov.

By andrew
(144 views)

Korean Biotech Industry in 2004 - Past, Now, & Future -

Korean Biotech Industry in 2004 - Past, Now, & Future -

Korean Biotech Industry in 2004 - Past, Now, & Future -. March 2004. Notice. These slides are only for the presentation at the 8 th Nomura Bio Conference Asia Pacific 2004, written by Byong Seung Cho, an investment associate at Korea Technology Investment Corp.

By naasir
(70 views)

The Cost of Developing a New Drug Has Greatly Increased

The Cost of Developing a New Drug Has Greatly Increased

The Cost of Developing a New Drug Has Greatly Increased. Cost to Develop One New Drug 1. Billions (Constant Dollars, Year 2000).

By Faraday
(68 views)

Fraud & Misconduct at Investigator Sites

Fraud & Misconduct at Investigator Sites

Fraud & Misconduct at Investigator Sites. Paul Below Medical Affairs - 3M Pharmaceuticals Presented to the Great Plains Chapter ACRP March 27, 2003. Disclaimer / Disclosure.

By JasminFlorian
(357 views)

Track E: Rapporteur Summary Pierre Barker

Track E: Rapporteur Summary Pierre Barker

Track E: Rapporteur Summary Pierre Barker. Track E: Rapporteur Summary. Role of health systems in providing high quality care to all who need it The financing of health systems that provide HIV care Operations Research on quality of care, universal coverage, and financing. Track E.

By MikeCarlo
(165 views)

Mining Frequent Patterns and Association Rules

Mining Frequent Patterns and Association Rules

Mining Frequent Patterns and Association Rules. CS 536 – Data Mining These slides are adapted from J. Han and M. Kamber’s book slides (http://www-faculty.cs.uiuc.edu/~hanj/bk2/). What Is Frequent Pattern Analysis?.

By tatiana
(155 views)

Labor Forecasting at Eli Lilly and Company

Labor Forecasting at Eli Lilly and Company

Labor Forecasting at Eli Lilly and Company. Kevin Ross Assistant Professor Information Systems and Technology Management UCSC. Outline. About Eli Lilly and Company The Tippecanoe Manufacturing Facility Decision Science Team Forecasting Challenge Solution and Recommendations

By loretta
(206 views)

3D Structures of Biological Macromolecules Part 3: Drug Research and Design

3D Structures of Biological Macromolecules Part 3: Drug Research and Design

3D Structures of Biological Macromolecules Part 3: Drug Research and Design. Jürgen Sühnel jsuehnel@fli-leibniz.de. Leibniz Institute for Age Research, Fritz Lipmann Institute, Jena Centre for Bioinformatics Jena / Germany. Supplementary Material: www.fli-leibniz.de/www_bioc/3D/.

By paul
(182 views)

Drawing Conclusions and Identifying Bias and Errors…

Drawing Conclusions and Identifying Bias and Errors…

Drawing Conclusions and Identifying Bias and Errors…. A good experiment is designed so the experimenter can reach a valid conclusion. A valid conclusion is one the experimenter and other people can trust.

By jerod
(131 views)

View New drug PowerPoint (PPT) presentations online in SlideServe. SlideServe has a very huge collection of New drug PowerPoint presentations. You can view or download New drug presentations for your school assignment or business presentation. Browse for the presentations on every topic that you want.